Trial Profile

Oral ONCE Daily prophylaxis with PHA-022121 in Patients with Acquired C1-Inhibitor Deficiency

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deucrictibant (Primary)
Indications Angioedema
Focus Therapeutic Use
Acronyms ONCE-AID

Most Recent Events

25 Mar 2024 Last checked against European Clinical Trials Database record.
23 Mar 2024 Planned End Date changed from 28 Apr 2024 to 28 Nov 2024.
06 May 2023 According to a Pharvaris media release, Pharvaris provided PHVS416 (immediate-release deucrictibant capsules) for this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com